-transparent.png){kind=logo}
The reaction of the renin-angiotensin system to acute angiotensin converting enzyme inhibition was investigated in a single-blind, crossover study in nine normal volunteers receiving two out of three regimens in random order: the new converting enzyme inhibitor benazepril (20 mg once or 5 mg four times at 6-hour intervals) or enalapril (20 mg). Plasma converting enzyme activity, drug levels, angiotensin I and angiotensin II, active renin, and aldosterone were measured before and 1-4 hours and 14-30 hours after drug intake. Baseline in vitro plasma converting enzyme activity was 97 +/- 15 nmol/ml/min (mean +/- SD) when Hip-Gly-Gly was used as substrate, but with carbobenzoxy-Phe-His-Leu (Z-Phe-His-Leu) or angiotensin I as substrate it was only 20 +/- 4 and 1.7 +/- 0.3 nmol/ml/min, respectively. Discriminating power at peak converting enzyme inhibition was enhanced with the two latter substrates. In vivo converting enzyme activity was estimated by the plasma angiotensin II/angiotensin I ratio, which correlated well with in vitro converting enzyme activity using Z-Phe-His-Leu as substrate (r = 0.76, n = 252). Angiotensin II levels returned to baseline less than 24 hours after drug administration, whereas in vitro and in vivo converting enzyme activity remained considerably inhibited and active renin together with angiotensin I levels were still elevated. A close linear relation was found between plasma angiotensin II and the angiotensin I/drug level ratio (r = 0.91 for benazeprilat and r = 0.88 for enalaprilat, p less than 0.001). Thus, plasma angiotensin II truly reflects the resetting of the renin-angiotensin system at any degree of converting enzyme inhibition. The ratio of plasma angiotensin II to angiotensin I represents converting enzyme inhibition more accurately than in vitro assays, which vary considerably depending on substrates and assay conditions used.
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
May 2005,
Circulation,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
September 2002,
Journal of the American Society of Nephrology : JASN,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
February 2009,
Hypertension (Dallas, Tex. : 1979),
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
March 1988,
The American journal of medicine,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
October 1993,
Fiziologicheskii zhurnal imeni I.M. Sechenova,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
January 2000,
Terapevticheskii arkhiv,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
February 1993,
Journal of cardiovascular pharmacology,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
April 1989,
American journal of hypertension,
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
December 1980,
Clinical science (London, England : 1979),
L Juillerat, and
J Nussberger, and
J Ménard, and
V Mooser, and
Y Christen, and
B Waeber, and
P Graf, and
H R Brunner
January 1989,
Peptides,
